Key facts
- Notable investors include WOW Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Peptirna Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Peptirna Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Peptirna Therapeutics
Developer of peptide-based siRNA drug delivery technologies designed to enable targeted RNA interference therapies beyond liver cells. The company has developed a delivery vehicle that combines custom peptides with siRNA drugs to transport them into target cells outside the liver and incorporates technology to help siRNA escape endosomal degradation after cellular uptake, enabling biotechnology and pharmaceutical developers to broaden and optimize siRNA therapeutics.
- Sector
- Healthcare
- HQ
- Seongnam, South Korea
- Ownership
- Privately Held (backing)
Peptirna Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Peptirna Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Peptirna Therapeutics in its N-PORT filings yet. We sweep new filings monthly.